Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Translate Bio

Translate Bio
2010 FOUNDED
PUBLIC STATUS
81-90 EMPLOYEES
TBIO STOCK SYMBOL
1 INVESTMENTS
$9.20 SHARE PRICE (As of Friday Closing)
Description

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Formerly Known As
RaNA Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 29 Hartwell Avenue
  • Lexington, MA 02421
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Translate Bio’s full profile, request a free trial.

Translate Bio Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$4.81 - $16.60 $468M $9.22 -$3.16 225K 50.9M

Translate Bio Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 317,236 473,407
Revenue 2,894 1,420 0 0
EBITDA (112,757) (101,442) (77,620) (26,082)
Net Income (109,384) (97,395) (66,443) (26,698)
Total Assets 277,736 287,651 198,547 205,563
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Translate Bio Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Translate Bio‘s full profile, request access.

Request full access to PitchBook

Translate Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Translate Bio‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Translate Bio Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sutro Biopharma Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000000000 Venture Capital-Backed Houston, TX 000.00 00000000000 000.00
0000000 00000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
000000 0000000000 Formerly VC-backed Oslo, Norway 00 00000 000000000 00000
00000 Private Equity-Backed San Diego, CA 00 0000 0000000 0000 0000
To view this company’s complete list of competitors, request access »

Translate Bio Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 (000 0000000 04-Jan-2017 000000000 00000 00 Biotechnology 000000 000000 00.
To view this company’s complete investment and acquisition history, request access »

Translate Bio Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Translate Bio‘s full profile, request access.

Request full access to PitchBook

Translate Bio Executive Team (17)

Name Title Board
Seat
Contact
Info
Ronald Renaud Jr. Chief Executive Officer & Board Member
John Schroer Chief Financial Officer
Paula Cloghessy Chief Human Resources Officer
Paul Burgess JD Chief Legal Officer
Richard Wooster Ph.D Chief Scientific Officer

6 Former Executives

You’re viewing 5 of 17 executives. Get the full list »

Translate Bio Board Members (12)

Name Representing Role Since Contact
Info
Ankit Mahadevia MD Atlas Venture Board Member 000 0000
Brian Gallagher Ph.D SR One Board Member 000 0000
Daniel Lynch Self Chairman 000 0000
Iain Dukes Ph.D Self Board Member 000 0000
Joshua Resnick MD Self Board Member 000 0000

6 Former Board Members

You’re viewing 5 of 12 board members. Get the full list »